Antegenes

Antegenes is a health technology company established in 2018 as a spin-off from the University of Tartu in Estonia. The company was founded by Dr. Peeter Padrik, a medical doctor, researcher, and the current CEO, to make broad genetic information accessible for clinical use in healthcare. After a two-year research and development phase, Antegenes launched CE-marked in vitro diagnostic polygenic risk tests in Europe in 2020.

The firm specializes in developing and implementing genetic tests based on polygenic risk score (PRS) technology to facilitate the personalized prevention and early detection of common cancers. The PRS technology analyzes hundreds to thousands of genetic variants to calculate an individual's inherited risk of developing a particular disease. Antegenes offers at-home genetic tests that assess an individual's risk for major cancers, including breast, prostate, colorectal, and melanoma. These tests provide a risk assessment and include clinical recommendations for a personalized cancer prevention plan. The company's business model involves selling these test kits directly to consumers and partnering with healthcare professionals and clinics. Antegenes' solutions are also available as CE-marked software as a medical device for genetic analysis of existing data.

The company targets both individual consumers and healthcare systems. For example, the Estonian Health Insurance Fund accepts Antegenes' PRS report to recommend earlier public breast cancer screening for high-risk individuals. Antegenes has expanded its operations from Estonia to the United Kingdom, Sweden, Norway, Portugal, Spain, and plans to enter the German market. The company has secured funding through several rounds, including a seed round in 2022 that raised €2.3 million from investors like Pipedrive co-founder Timo Rein, Enterprise Estonia, and the European Institute of Innovation and Technology (EIT Health).

Keywords: polygenic risk score, genetic testing, cancer prevention, personalized medicine, health technology, precision prevention, breast cancer risk, prostate cancer risk, colorectal cancer risk, melanoma risk, CE-marked medical device, in vitro diagnostics, genetic risk assessment, early cancer detection, genomics, clinical recommendations, DNA analysis, Tartu, Estonian startup, Peeter Padrik